Author Archives: admin


Quris-AI’s Bio-AI Platform Integrated by Merck KGaA, Darmstadt, Germany for Preclinical Small Molecule Drug Safety Evaluation

Quris-AI to Provide Safety Assessments for Small Molecule Drug Candidates Before Initiating Clinical Trials Quris-AI to Provide Safety Assessments for Small Molecule Drug Candidates Before Initiating Clinical Trials

See original here:
Quris-AI's Bio-AI Platform Integrated by Merck KGaA, Darmstadt, Germany for Preclinical Small Molecule Drug Safety Evaluation

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.

Continue reading here:
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of January 2, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Continued here:
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

IRVINE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. The offering closed on January 7, 2025.

Go here to see the original:
AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced successful completion of the six-patient Phase 1b safety run-in segment in the U.S. NEXICART-2 study of NXC-201, an investigational CAR-T therapy, in patients relapsed/refractory (R/R) AL Amyloidosis. Achievement of this milestone is expected to accelerate enrollment across U.S. study sites beginning in January 2025.

Continued here:
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Clearmind Medicine Announces Shareholders Meeting Results

Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on January 6, 2025 (the “Meeting”), as set out in the Company’s Management Information Circular dated December 1, 2024, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at five members, the election of directors of the Company for the ensuing year, to appoint Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, as auditor of the Company, a resolution to establish and approve an omnibus equity incentive plan and a resolution allowing the directors, if they deem such an action to be in the best interest of shareholders, effect a consolidation (the “Consolidation”) of the common shares in the capital of the Company (the “Shares”) on the basis of fifty (50) pre-Consolidation Shares for one (1) post-Consolidation Share, or such other lesser consolidation ratio as determined by the Company’s board of directors.

See the rest here:
Clearmind Medicine Announces Shareholders Meeting Results